De Novo device
Nerivio Migra
Theranica Bioelectronics , Ltd. · Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT, Class II) · First FDA decision May 20, 2019, newest May 20, 2019Migraine and headache
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
2
Naming "Nerivio Migra"
MAUDE reports
0
Brand "Nerivio Migra", since 2015
PubMed studies
0
Mentioning "Nerivio Migra"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Nerivio Migra
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Nerivio MigraNew device typeDe Novo
DEN180059 · Decided May 20, 2019 · 195 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Nerivio Migra", any status and sponsor, newest update first.
- Migraine Treatment With Nerivio Migra Neurostimulation DevicePivotal-lookingTerminated
TheranicaNot on our public-company list
NCT03076515 · 120 participants · Start Apr 2, 2017 · Primary completion Jan 31, 2018
Device: Nerivio Migra neurostimulation; Sham Nerivio Migra · For: Acute Migraine
Sites: Washington D.C., District of Columbia; Albany, New York; Hartford, New York · 8 sites in all
- Evaluation of a Novel Device for Treatment of Migraine HeadachePivotal-lookingCompleted
TheranicaNot on our public-company list
NCT03361423 · 296 participants · Start Dec 17, 2017 · Primary completion Nov 25, 2018
Device: Nerivio Migra-1 active device; Nerivio Migra-1 Sham device · For: Migraine Without Aura; Migraine With Aura
Sites: Hartford, Connecticut; Springfield, Missouri; St Louis, Missouri · 12 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Nerivio Migra", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QGT
7 reports: 3 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Nerivio Migra"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QGT.
- NerivioTheranica Bio-Electronics, Ltd. · 510(k) 2025
- NerivioInfinityTheranica Bioelectronics , Ltd. · 510(k) 2023
- NerivioTheranica Bioelectronics , Ltd. · 510(k) 2023
- Nerivio, FGD000075-4.7Theranica Bioelectronics , Ltd. · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.